Venezuela Unannounced Inspections 2026: SACS Audit Powers over Device Importers

1. Key takeaways

The Venezuelan authority has the power to inspect medical device importers at any time without prior notice, whether framed as an audit or as an inspection visit. That power forms part of the supervisory and inspection functions exercised by SACS.

The conclusion is this: the absence of prior notice means compliance has to be a permanent condition rather than a state of readiness for an announced visit. Any compliance management model that depends on tidying up before an inspection does not work in Venezuela, because there is no window in which to tidy up. The distinction matters more than it appears: an announced inspection rewards preparation, while an unannounced one rewards design. Only a system that is correct on an ordinary Tuesday survives.

Practically, this shifts the investment from inspection response to document architecture. A manufacturer that can retrieve a valid certificate, a batch record and a label authorization within minutes is compliant in the sense that matters here; one that can produce them after two weeks of internal correspondence is not, even if the underlying facts are equally sound.

2. Legal basis

Position statement: the ability to inspect importers at any time without prior notice derives from industry descriptions of Venezuelan supervisory powers and is marked as a practical estimate.

The legal basis is cumulative rather than specific. Decreto N° 472 supplied the original supervisory and inspection grant; the health organization law supplied the statutory foundation for regulating health products; the 2006 organic regulation supplied the organizational unit that carries the function; and the 2026 circular supplied the current policy emphasis on technical sanitary standards at the point of entry. No single instrument states a notice period, which is consistent with the description of the power as exercisable at any time.

3. Expert insights

1. The inspection target is the importer, not the foreign manufacturer. This is the key distinction in the whole arrangement: the inspection power operates directly on the domestic importer and license holder. A foreign manufacturer falls outside the direct scope of inspection, but findings travel back to the manufacturer through the license holder, in the form of requests for additional documents, demands for recall, or effects on the status of the certificate. The manufacturer therefore carries the consequences of an inspection it cannot attend and cannot prepare for, which is precisely why the contractual allocation of inspection obligations deserves the same attention as the commercial terms.

2. The inspection power and the internal inspection function corroborate each other. SACS hosts an inspection and technovigilance department, and industry sources record that it can inspect without notice. Taken together, the two facts establish that this is not a power on paper but a power with an executing body. A department with staff, a routine workflow and enforcement capacity behaves differently from a legal provision without one: it produces findings on a schedule, and it follows them up.

3. Inspection content typically covers traceability and document consistency. Read against the Circular DGSACS-008/2026 requirements on traceability, product origin and manufacturing information, the likely focus areas are the consistency between imported goods and what the certificate records, the completeness of batch records, the validity of the label authorization, and the maintenance of adverse event records. Each of those four items is a comparison rather than a document in isolation, which means a single mismatch between two otherwise valid documents is the most probable finding.

4. Permanent readiness means documents can be produced on demand. Because there is no preparation time, compliance management has to guarantee that certificates and permits are within validity and immediately retrievable, that batch records can be consulted at any moment, that adverse event and complaint records are continuously maintained, and that label authorization files are archived in order. These requirements point to document management capability rather than to the content of the documents themselves. A manufacturer can hold excellent content in an unsearchable archive and still fail the test that an unannounced visit applies.

One further point concerns who represents the company during a visit. Where the license holder is a distributor without dedicated regulatory staff, the person who receives the inspectors may be a commercial manager who cannot answer questions about batch records or label authorization. Naming a regulatory contact and a deputy, and recording that arrangement in the agreement, prevents an inspection from turning into an improvised conversation between parties who do not share a vocabulary. The cost of that arrangement is negligible; the cost of its absence is often a finding that could have been closed on the spot.

4. Practical recommendations

1. Manufacturers: require in the agreement with the license holder or importer that a permanent state of compliance be maintained, and reserve a periodic manufacturer verification right.
2. License holders: maintain an immediately retrievable document set covering certificates, import permits, label authorizations, batch records, adverse event records and complaint handling records.
3. Regulatory affairs leads: run a compliance verification of the license holder at least once a year, with verification items aligned to the focus areas of SACS inspections.
4. Quality teams: set remediation deadlines for identified compliance gaps and track them to closure, rather than waiting for an inspection to force the issue.

5. Verification checklist

• □ The license holder agreement provides for a permanent compliance obligation and a manufacturer verification right
• □ An immediately retrievable document set exists and covers six document categories
• □ An annual manufacturer compliance verification mechanism is in place
• □ Remediation deadlines and closed-loop tracking are configured for compliance gaps
• □ Inspection focus areas have been aligned with Circular DGSACS-008/2026

Regulatory information verified as of October 29, 2026

All conclusions published here defer to the current regulatory texts as issued by the competent authority, verified item by item before delivery.

— GRZAN Regulatory Team

GRZAN supports medical device and IVD manufacturers, importers and authorized representatives with registration and post-market compliance in Venezuela: dossier preparation and filing through the SACS and COMEX channels, license-holder coordination, technovigilance and adverse event workflows, recall and field corrective action planning, inspection readiness, and continuous monitoring of circulares and decrees. For tailored support on your Venezuela portfolio, contact the GRZAN regulatory team at info@grzanglobal.com.